Key result
Early initiation of dabigatran after acute ischemic stroke or TIA was associated with a lower hazard for intracranial hemorrhages compared to VKA use (HR 0.47; 95% CI 0.10-2.21).
Why the study?
The optimal timing of initiating or resuming anticoagulation after acute ischemic stroke or transient ischemic attack in patients with atrial fibrillation is debated.
Does early or late initiation of dabigatran reduce major hemorrhagic events compared to VKA in patients with acute ischemic stroke or TIA and atrial fibrillation?
Observational (n=3,312)
Yes
Does early or late initiation of dabigatran reduce major hemorrhagic events compared to VKA in patients with acute ischemic stroke or TIA and atrial fibrillation?
Hazard Ratio: 0.47 (95% CI 0.1–2.21)
Early application of dabigatran appears safer than VKA regarding hemorrhagic complications after acute ischemic stroke or TIA, though estimates have low precision.
No takes yet. Share an insight, caveat, or question.
Early dabigatran may lower ICH hazard versus VKA post-stroke/TIA; leaves open optimal timing and requires randomized confirmation.
Große et al. (2023) conducted an observational in Acute ischemic stroke or transient ischemic attack (n=3,312). Early initiation of dabigatran (⩽ 7 days) vs. Vitamin K antagonists (VKA) initiated at any time was evaluated on Intracranial hemorrhages (HR 0.47, 95% CI 0.10-2.21). Early initiation of dabigatran after acute ischemic stroke or TIA was associated with a lower hazard for intracranial hemorrhages compared to VKA use (HR 0.47; 95% CI 0.10-2.21).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: